Please read the following news media article:
How Much Can IVF And Other Assisted Reproductive Technologies Alleviate Singapore’s Demographic Crisis?
Summary: Singapore is confronting a profound demographic crisis, with its total fertility rate (TFR) falling to a historic low of 0.87 in 2025. In response, the government has established the Marriage and Parenthood Reset Workgroup to galvanize societal support and formulate comprehensive policy interventions. Expanding access to in vitro fertilization (IVF) and other assisted reproductive technologies (ARTs) by enhancing subsidies and loosening laws and regulations are anticipated to be key recommendations. This white paper critically examines the efficacy and broader implications of such policy actions. Analysis of international data reveals that IVF and other ARTs contribute modestly to overall live births, rendering them insufficient as a stand alone solution for reversing demographic decline. Furthermore, policies such as extending public co-funding to private clinics, normalizing preimplantation genetic testing for aneuploidy (PGT-A), and subsidizing elective egg freezing present significant clinical, ethical, and economic challenges. The paper also explores the complexities surrounding egg and sperm donation, the risks of permitting surrogacy, the legal inconsistencies of permitting non-traditional family formation via IVF/ARTs, and Singapore's strategic approach to newly emerging ARTs such as in vitro gametogenesis (IVG) and mitochondrial transfer therapy (MRT). A nuanced, evidence-based strategy that prioritizes public healthcare infrastructure, holistic family planning support, and integrated legal reforms is recommended to secure Singapore's long-term demographic vitality.
Keywords: Assisted Reproductive Technologies; Demographic Crisis; Fertility Policy; In Vitro Fertilization; Singapore; Total Fertility Rate.
1. Introduction
Singapore is confronting a profound demographic crisis, epitomized by its total fertility rate (TFR) plummeting to an unprecedented low of 0.87 in 2025, a significant drop from 0.97 in 2024 [1]. This alarming figure, substantially below the replacement level of 2.1, poses an existential threat to the nation's long-term societal and economic sustainability. The declining citizen population growth rate has prompted urgent governmental action. In April 2026, the government established the Marriage and Parenthood (M&P) Reset Workgroup, chaired by Minister Indranee Rajah, to develop a whole-of-society approach to better support Singaporeans in their marriage and parenthood journeys [2]. The workgroup aims to develop a long-term roadmap, propose policy enhancements addressing key concerns such as financial costs and work-life support, and mobilize society to reverse the declining fertility trajectory [2].
In response to this persistent decline, governmental discourse and policy proposals are increasingly focusing on medical interventions related to Assisted Reproductive Technologies (ARTs). The anticipated policy actions are likely to center on enhancing the accessibility of IVF/ARTs through expanded subsidies, financial support, and a liberalization of existing restrictive regulations. However, a comprehensive analysis reveals that such an approach necessitates careful consideration of several crucial caveats and potential pitfalls that must precede any broad policy implementation.
This white paper critically examines the efficacy and broader implications of expanding IVF/ARTs accessibility and related policies in addressing Singapore's declining fertility rate. It argues that while IVF/ARTs offer valuable solutions for individuals and couples facing infertility, their capacity to significantly alter national demographic trends is inherently limited. Furthermore, the paper delves into specific policy debates, including the extension of IVF co-funding to private clinics, the normalization of Preimplantation Genetic Testing for Aneuploidy (PGT-A), and the provision of subsidies for elective egg freezing. It also explores the complex ethical and practical considerations surrounding gamete donation, the potential societal impacts of permitting surrogacy and encouraging non-traditional family formations, and Singapore's strategic approach to emerging ARTs. By highlighting these multifaceted challenges, this research aims to provide a nuanced perspective for policy deliberation by the M&P Reset Workgroup, ensuring that interventions are not only effective but also ethically sound, cost-efficient, and aligned with Singapore's broader societal objectives.
2. The Limited Impact of Expanding Accessibility to IVF/ARTs
While IVF and other ARTs represent a beacon of hope for many individuals and couples struggling with infertility, their potential to significantly reverse a nation's declining fertility rate is often overstated in public discourse. International data consistently demonstrates that the contribution of IVF/ARTs to a country's total live births is relatively modest. In most developed nations, IVF/ARTs account for approximately 2% to 5% of all live births annually [3]. Even in countries with highly developed, heavily subsidized, and accessible IVF/ARTs programs, such as Denmark, this figure rarely exceeds 10% [4].
Given that Singapore's TFR has fallen to 0.87, a level far below the replacement rate, a contribution of this magnitude from IVF/ARTs alone is inherently insufficient to substantially improve the national TFR and address the demographic crisis [1]. The mathematical reality dictates that even a significant percentage increase in IVF/ARTs-conceived births would translate to only a marginal absolute increase in the national TFR. Therefore, relying on IVF/ARTs expansion as a primary demographic lever is a mathematically flawed strategy.
Furthermore, increasing public funding for IVF/ARTs often encounters the challenge of diminishing returns. As subsidies and financial assistance expand, they tend to be directed towards more complex and expensive procedures. These advanced treatments, while crucial for a smaller cohort of patients with severe or refractory fertility issues, typically yield lower success rates per cycle and higher costs per live birth compared to simpler interventions. Consequently, a larger investment of public funds may benefit a progressively smaller pool of patients, leading to a less cost-effective allocation of resources from a public health perspective aimed at boosting overall birth rates [5].
The demand for IVF and other ARTs in Singapore is undeniably growing. Data indicates that approximately 10,500 cycles of IVF/ARTs treatments were carried out in Singapore in 2022, representing a 14% increase from 2020 and an 81% jump from 2013 [6]. To meet this demand, public hospitals, including KK Women's and Children's Hospital (KKH), National University Hospital (NUH), and Singapore General Hospital (SGH), are expanding their IVF capacity by approximately 20% [6]. However, it is critical to distinguish between fulfilling individual medical needs and achieving macroeconomic demographic goals. The expansion of capacity and funding must be evaluated through the lens of cost-benefit ratios when considering broad-based IVF/ARTs subsidy expansions as a primary demographic intervention.
3. Policy Debates and Challenges in Expanding Accessibility to IVF/ARTs
The discourse surrounding IVF/ARTs policies in Singapore extends beyond the general expansion of access to encompass specific contentious areas. These include proposals to extend public co-funding for IVF to private clinics and the normalization of Preimplantation Genetic Testing for Aneuploidy (PGT-A). Both areas present significant challenges that require careful policy navigation.
3.1. Extending IVF Co-funding to Private Fertility Clinics
A significant point of advocacy among aspiring parents in Singapore is the extension of existing public hospital IVF co-funding schemes to private fertility clinics. Currently, the government co-funds up to 75% of the cost for eligible couples undergoing IVF at public assisted reproduction centers, covering up to SGD 7,700 for a fresh cycle [6]. Proponents argue that extending these subsidies to the private sector would alleviate perceived waiting times in public institutions and provide access to what is regarded as more personalized medical services. This argument is often framed around patient choice and convenience.
However, this proposal introduces a fundamental contradiction within Singapore's healthcare financing philosophy. The current system generally prioritizes public subsidies for life-threatening conditions such as cancer and heart disease within public hospitals, where cost-effectiveness and equitable access are paramount. Extending similar substantial subsidies to private entities, which are primarily driven by shareholder profitability, raises significant questions regarding the optimal allocation of public funds. Critics argue that if additional resources are to be deployed, they might be more effectively utilized by enhancing and expanding IVF services within public hospitals, thereby strengthening the public healthcare system and ensuring broader, more equitable access without the inherent profit motives of private providers.
Furthermore, the premise of long waiting times in public hospitals is increasingly contested by recent data. In April 2024, the Ministry of Health reported that the median and mean wait times across public hospitals for the first assisted reproductive treatment appointment in 2023 were no more than seven and 12 days, respectively [7]. At KKH, there is currently no wait time for couples starting IVF/ARTs treatment [6]. Given these improvements in public sector efficiency, the argument for subsidizing private care based on access delays is significantly weakened. Recent policy changes, such as the new Integrated Shield Plan rider rules introduced in April 2026 to manage the shift of patients from private to public healthcare due to rising insurance premiums, further underscore the governmental sensitivity around public funding in private healthcare settings [8].
3.2. Normalizing Preimplantation Genetic Testing for Aneuploidy (PGT-A) as a mainstream clinical procedure
Another highly contentious issue is the normalization of Preimplantation Genetic Testing for Aneuploidy (PGT-A) for the genetic screening of IVF embryos. PGT-A is a technique used to identify chromosomal abnormalities in embryos before implantation. Advocates in Singapore often highlight the rising trend of older motherhood, which is associated with an increased risk of chromosomal conditions such as Down syndrome, as a primary justification for its widespread application. There have been calls to financially assist older women undergoing PGT-A, either through direct subsidies or the use of MediSave.
Despite these arguments, several significant concerns surround the routine use of PGT-A. The Practice Committees of the American Society for Reproductive Medicine (ASRM) and the Society for Assisted Reproductive Technology (SART) published a committee opinion in 2024 stating that "the value of PGT-A as a routine screening test for all patients undergoing in vitro fertilization has not been demonstrated" [9]. Numerous large-scale, multi-center randomized controlled trials globally have consistently shown that PGT-A does not significantly improve overall IVF success rates, particularly in terms of cumulative live birth rates.
A landmark study published in The British Medical Journal in December 2025 by Lin and colleagues evaluated PGT-A versus no genetic testing in couples undergoing intracytoplasmic sperm injection (ICSI) for severe male infertility. The multicentre randomized controlled trial found that the cumulative live birth rates per woman were 60.4% in the PGT-A group and 60.9% in the no PGT-A group, showing no significant difference (P=0.92) [10]. The authors concluded that PGT-A did not improve live birth rates compared to routine ICSI alone, although it did reduce the rates of clinical pregnancy loss [10]. Consequently, major professional bodies caution against its widespread and injudicious application, emphasizing that its value as a routine IVF screening tool remains unclear.
Concerns also persist regarding the reliability of PGT-A. There have been allegations of misdiagnosis, leading to the discarding of potentially viable IVF embryos. A notable example is the AU$56 million no-admission-of-liability settlement reached by Australian fertility company Monash IVF in August 2024 with over 700 former patients [11]. The class-action lawsuit alleged that the company used inaccurate genetic testing, resulting in the destruction of potentially viable embryos and compromising patients' chances of parenthood [11]. Such incidents underscore the ethical, emotional, and legal complexities, as well as the potential for significant harm, associated with the uncritical adoption and subsidization of PGT-A. Implementing policies that encourage the widespread use of PGT-A without rigorous regulatory oversight and proven efficacy could expose patients to unnecessary risks and lead to the inefficient use of public healthcare funds.
3.3. Overcoming the Persistent Shortage of Donated Sperm, Eggs, and Embryos
Singapore faces a severe and persistent shortage of donated sperm, eggs, and embryos for infertile IVF patients. This scarcity is primarily attributed to strict prohibitions on monetary compensation for donors, a stance previously upheld by the Bioethics Advisory Committee (BAC), which deemed such payments as undue financial inducements [12]. While the intention behind this policy is to prevent the commodification of human biological material and exploitation, its practical consequence is a critically limited supply of donor gametes, leaving many infertile individuals without viable options for family formation.
With the legalization of elective egg freezing (EEF) from July 2023 for women aged 21 to 37, regardless of marital status [13], a gradual accumulation of unused frozen eggs is anticipated [14]. These unused frozen eggs could potentially serve as a vital source for donation to infertile older women with poor-quality eggs. This scenario has sparked a debate regarding partial compensation for former elective egg-freezing patients who choose to donate their unused frozen eggs.
Proponents argue that such compensation would reimburse them for medical fees already incurred during the egg freezing process, thereby incentivizing donation and alleviating the critical shortage without violating the spirit of non-commodification [14]. Conversely, it is argued that individuals incur these medical fees for their own reproductive goals, and a subsequent decision to donate does not retroactively transform private treatment costs into donation-related expenses, thus maintaining the strict principle against financial inducement [15]. This ethical dilemma requires careful navigation by policymakers to balance the pressing need for donor gametes with established bioethical principles.
3.4. Expanding Accessibility to Elective Egg Freezing (EEF)
Calls for government subsidies and financial assistance for elective egg freezing are gaining traction, with advocates arguing that such support would enable younger women with fewer financial resources to undergo the expensive procedure when their egg quality is optimal. The rationale often presented is to provide women with greater reproductive autonomy and flexibility in family planning, particularly in a society where career aspirations and the search for a compatible partner may delay childbearing.
However, a fundamental contradiction exists when considering public funding for elective egg freezing: the overwhelming majority of women who freeze their eggs do not eventually use them. Overseas studies consistently show low utilization rates, with estimates suggesting that, at best, only one in five women will ultimately utilize their frozen eggs [16]. A 2025 study highlighted that return rates were highest among women who froze eggs between the ages of 38 and 42, but even these cohorts showed return rates of only around 7.9% to 8.0% [17]. This low utilization rate raises significant concerns about the potential for a substantial waste of public subsidies or MediSave funds if such programs were widely implemented.
Furthermore, the primary justification for elective egg freezing—the need for more time to find a compatible life partner—is problematic. In many countries, including Singapore, more women graduate from universities than men, contributing to a "mating gap" due to traditional expectations of women marrying men with equal or higher education [18]. This persistent incompatibility in marriage expectations cannot be resolved by expanding access to egg freezing, which merely defers the decision rather than addressing the underlying societal factors contributing to delayed family formation. Policy interventions might be more effective if directed toward addressing the root causes of the mating gap and fostering supportive environments for early family formation.
3.5. Permitting Surrogacy
Currently, surrogacy is not permitted under Singapore's clinic licensing rules, effectively prohibiting domestic surrogacy arrangements. The question of permitting surrogacy for infertile patients, whether altruistic or commercial, raises significant ethical, legal, and social concerns. While surrogacy could offer a pathway to parenthood for those unable to carry a pregnancy, there is a substantial risk that even an "altruistic" arrangement could inadvertently morph into a commercial transaction, especially given the high demand and emotional stakes involved [19].
A significant risk lies in the potential emergence of agencies that covertly source surrogate mothers, particularly from less economically developed countries, for Singaporean couples. This could involve clandestine payments to impoverished foreign women, leading to their exploitation and raising serious human rights concerns [20]. Furthermore, such transnational arrangements carry the potential for complex diplomatic fallout from child-custody disputes between Singaporean commissioning parents and foreign surrogate mothers, as legal frameworks and parental rights vary significantly across jurisdictions [21]. The ethical complexities and potential for exploitation necessitate extreme caution; any consideration of surrogacy would require robust, likely restrictive, regulatory frameworks that may be difficult to enforce internationally.
3.6. Permitting Non-Traditional Family Formation via IVF and Other ARTs
The contentious issue of encouraging non-traditional family formation, specifically by permitting single women and same-sex partners to access IVF and other ARTs in Singapore, necessitates concurrent and consistent policy changes across various legal domains. The current legal landscape in Singapore is largely predicated on a traditional family unit. While single women can now freeze their eggs, they are currently not permitted to use them for IVF unless they are legally married [13].
Permitting IVF for same-sex partners would be incongruous if same-sex marriages remain prohibited, creating a legal and social disconnect regarding the recognition of such families [22]. Similarly, permitting single women to undergo sperm donor IVF would directly contradict current public housing policies that often disadvantage unmarried mothers, impacting their access to affordable housing and other social benefits [23]. Any move towards liberalizing IVF/ARTs access for non-traditional family structures must therefore be accompanied by a comprehensive review and reform of existing laws and policies to ensure legal consistency, prevent discrimination, and provide adequate support for all family types. Without such holistic policy alignment, these interventions risk creating new forms of inequality and social friction.
3.7. Investing in Newly Emerging Assisted Reproductive Technologies
The landscape of Assisted Reproductive Technologies is continuously evolving, with several groundbreaking techniques on the horizon. Singapore must strategically consider its engagement with these emerging ARTs, particularly In Vitro Gametogenesis (IVG) and Mitochondrial Replacement Therapy (MRT), also known as 3-parent IVF.
In Vitro Gametogenesis (IVG) is a novel technology that holds the promise of creating functional sperm and eggs from other human body cells, such as skin cells [24]. This technology could revolutionize fertility treatment by offering solutions to individuals who are infertile due to a lack of viable gametes, including those who have undergone cancer treatment or are in same-sex relationships [25]. While IVG has shown promising results in animal studies, with researchers successfully producing functional oocytes from human skin cells in laboratory settings, its application in humans remains experimental [26]. It raises significant ethical considerations, particularly concerning the creation of embryos with genetic material from multiple sources or the potential for "designer babies" [27].
Mitochondrial Replacement Therapy (MRT), often referred to as "3-parent IVF," is another advanced ARTs that offers a potential solution for specific fertility challenges, particularly for older women with fewer and poorer quality eggs [28]. This technique involves transferring the nuclear DNA from an egg with faulty mitochondria into a donor egg with healthy mitochondria, which is then fertilized. The resulting embryo therefore has genetic material from three individuals: the nuclear DNA from both parents and the mitochondrial DNA from the donor [29]. This procedure has primarily been developed to prevent the transmission of severe mitochondrial diseases from mother to child, and successful births using this technique have been reported [30]. It also holds potential for older women with poor egg quality, as it could provide healthy mitochondrial contents from younger donors to improve embryo viability [28].
Given Singapore's current lack of significant research infrastructure and expertise in these highly specialized and nascent fields, attempting to lead the race in IVG and MRT research at this stage would likely be both financially prohibitive and strategically inefficient. A more prudent and cost-effective approach for Singapore might be to await the maturation of these technologies in other leading foreign research institutions. Rather than investing heavily in foundational research, Singapore could strategically monitor international developments, assess the long-term outcomes and ethical consensus, and then consider importing the technology through established channels once it is widely accepted and regulated, thereby benefiting from global advancements without incurring the substantial initial research and development costs and risks.
4. Economic Implications of Expanding Accessibility to IVF/ARTs
A critical dimension often overlooked in the discourse surrounding IVF/ARTs policy is the profound economic implication of large-scale, state-sponsored fertility treatments. While the ethical and clinical aspects dominate the headlines, the financial sustainability of expanding IVF/ARTs subsidies requires rigorous scrutiny, particularly in the context of Singapore's aging population and rising healthcare costs.
4.1. The Opportunity Cost of Public Healthcare Funds
Singapore's healthcare system is renowned for its efficiency and focus on achieving optimal health outcomes through prudent resource allocation. The core philosophy of this system is to ensure that essential, life-saving, and basic healthcare services remain affordable and accessible to all citizens. In this framework, the allocation of substantial public funds to subsidize IVF/ARTs, particularly in private settings or for advanced, unproven techniques, introduces a significant opportunity cost.
Every dollar spent on subsidizing expensive IVF cycles, elective egg freezing, or nascent technologies like PGT-A is a dollar that cannot be allocated to other pressing healthcare needs. As Singapore's population ages rapidly, the burden of chronic diseases, geriatric care, and long-term care facilities will increase exponentially. Diverting critical healthcare resources towards interventions that yield a relatively low number of live births per dollar spent may compromise the government's ability to adequately fund core medical services for the broader population. Policymakers must carefully weigh the marginal demographic benefit of expanded IVF/ARTs subsidies against the pressing needs of an aging society, ensuring that the pursuit of higher birth rates does not inadvertently undermine the overall resilience and equity of the public healthcare system.
4.2. Evaluating the Cost-Effectiveness of Fertility Interventions
To justify the expansion of public funding for IVF/ARTs, these interventions must be evaluated through rigorous health economic models, specifically focusing on the cost per additional live birth. Studies have shown that the cost-effectiveness of IVF/ARTs diminishes significantly with maternal age and the complexity of the required interventions. For younger women with straightforward tubal factor infertility, IVF is relatively cost-effective. However, as the average age of women seeking treatment increases—a trend clearly observed in Singapore, where the median age at first marriage was 29.3 years for women and 30.7 years for men in 2022 [6]—the success rates drop precipitously, while the costs escalate due to the need for multiple cycles, higher medication dosages, and advanced add-on treatments like PGT-A.
When the government co-funds up to 75% of these costs, it absorbs the financial risk of these lower-probability interventions. The cost per successful live birth for a woman over 40 utilizing multiple cycles of IVF with PGT-A is substantially higher than that for a younger woman. This economic reality necessitates a targeted approach to subsidies. Rather than a blanket expansion, financial support should be strategically directed towards demographic cohorts and medical indications where the clinical efficacy and cost-effectiveness are maximized. Implementing age-based eligibility criteria or tying subsidies to specific clinical prognoses, while potentially controversial, may be necessary to ensure the sustainable and responsible use of public funds.
5. The Necessity of a Holistic Societal Reset
Addressing Singapore's demographic crisis requires acknowledging that medical interventions, no matter how advanced or accessible, cannot overcome the fundamental societal and economic barriers to family formation. The Marriage and Parenthood Reset Workgroup must focus on a comprehensive societal reset that addresses the root causes of delayed childbearing and low fertility.
5.1. Addressing the "Mating Gap" and Educational Disparities
A significant structural barrier to family formation in Singapore is the phenomenon known as the "mating gap." As educational attainment among women has surged, surpassing that of men in many cohorts, traditional expectations regarding marriage have not evolved at the same pace. Many women still seek partners with equal or higher educational and economic status, while some men may be intimidated by highly educated or successful women. This mismatch leads to a growing segment of the population remaining single, not necessarily by choice, but due to a lack of perceived compatible partners.
Expanding access to elective egg freezing is often presented as a solution to this issue, providing women with "more time" to find a suitable partner. However, this is a technological response to a sociological problem. Egg freezing does not create compatible partners; it merely delays the confrontation with the mating gap. A true societal reset must involve cultural shifts that challenge traditional gender roles and expectations within marriage. Public campaigns and educational initiatives should promote the value of egalitarian partnerships, where shared values, mutual respect, and emotional compatibility are prioritized over traditional markers of status and income.
5.2. Transforming Work-Life Balance and Corporate Culture
Perhaps the most frequently cited barrier to parenthood in Singapore is the intense, demanding nature of the corporate culture. The pervasive long working hours, the expectation of constant connectivity, and the high stress associated with career advancement create an environment that is deeply hostile to family life. Many young couples, observing the struggles of their peers, actively choose to delay or forgo having children out of fear that they will be unable to balance the demands of work and parenting effectively.
While the government has introduced various pro-family policies, such as enhanced paternity leave and the Shared Parental Leave scheme, these legislative changes are often insufficient if they are not accompanied by a fundamental shift in workplace culture. Employees must feel empowered to utilize these benefits without fear of professional penalty or stigmatization. The M&P Reset Workgroup must engage closely with the business community to foster genuinely family-friendly workplaces. This includes promoting flexible working arrangements, outcome-based performance evaluations rather than mere presenteeism, and leadership that actively models and supports work-life balance. Only when the corporate culture genuinely supports parents can Singapore hope to see a sustainable increase in its fertility rate.
5.3. Reimagining the Cost of Raising a Child
Beyond the direct medical costs of conception, the perceived and actual costs of raising a child in Singapore are a major deterrent for prospective parents. The highly competitive education system, the prevalence of private tuition, and the high cost of living contribute to an environment where raising a child is viewed as an immense financial burden. The pressure to provide the "best" for a child, often defined by academic success and extracurricular achievements, creates a daunting financial and emotional threshold for parenthood.
To address this, the societal reset must encompass a broader conversation about the definition of success and the pressures placed on children and parents. The Ministry of Education's efforts to move away from an over-emphasis on academic grades are steps in the right direction, but deeper cultural changes are needed. Reducing the reliance on the shadow education system and fostering an environment where diverse pathways to success are valued can help alleviate the intense pressure and financial burden associated with child-rearing. Furthermore, continued efforts to ensure the affordability and accessibility of high-quality preschool and childcare services are essential to support working parents and reduce the early financial hurdles of parenthood.
6. Conclusion
Singapore's demographic challenge, marked by a critically low total fertility rate of 0.87, necessitates urgent and comprehensive policy responses. While Assisted Reproductive Technologies are a vital component of fertility care, a critical examination reveals that their expanded accessibility alone is unlikely to serve as a panacea for the nation's demographic decline. The inherent limitations of IVF/ARTs, contributing a relatively small percentage to overall live births, coupled with the diminishing returns of increased public funding, underscore the need for a nuanced policy approach.
This paper has highlighted several crucial caveats and potential pitfalls in current and proposed IVF/ARTs policies. Extending IVF co-funding to private clinics raises concerns about equitable resource allocation and the integrity of public healthcare financing, especially given the recent improvements in public hospital waiting times. The normalization of PGT-A is fraught with issues of inconclusive efficacy in improving live birth rates and reliability concerns, as evidenced by international studies and significant legal precedents. Furthermore, the persistent shortage of donated gametes, exacerbated by the prohibition of monetary compensation, and the low utilization rates of elective egg freezing challenge the cost-effectiveness and ethical justification of certain subsidy proposals. Broader societal implications, such as the risks associated with permitting surrogacy and the legal inconsistencies arising from encouraging non-traditional family formations, demand careful consideration and holistic policy reform.
For Singapore to effectively address its demographic future, policy deliberations by the Marriage and Parenthood Reset Workgroup must move beyond a singular focus on IVF/ARTs expansion. A more robust and ethically sound approach should prioritize public healthcare infrastructure by strengthening and expanding IVF/ARTs services within public hospitals to ensure equitable and cost-effective access, rather than diverting public funds to private clinics. Evidence-based IVF/ARTs adoption is equally essential, meaning that technologies such as PGT-A should be implemented only after rigorous evaluation of their proven efficacy in improving cumulative live birth rates and following the establishment of robust regulatory oversight to prevent misdiagnosis and ethical breaches. Policymakers should also engage in a comprehensive review of policies concerning donor compensation to address the critical shortage of gametes, balancing ethical concerns with the urgent demographic need. A cautious, wait-and-see approach for nascent technologies like IVG and 3-parent IVF is advisable, leveraging international research and importing proven technologies rather than investing in high-risk, early-stage domestic research and development. Finally, any policy changes related to IVF/ARTs for non-traditional family structures must be accompanied by comprehensive reforms in housing, marriage, and other relevant legal frameworks to ensure consistency and prevent discrimination.
Ultimately, Singapore's demographic future hinges not merely on increasing the number of births through medical means, but on fostering a supportive societal environment that encourages family formation and child-rearing through a multi-pronged strategy encompassing economic, social, and cultural reforms. A critical, evidence-based, and ethically informed approach to IVF/ARTs policies, integrated within a broader demographic strategy, is essential to navigate this complex challenge and secure Singapore's long-term vitality.
References
- Ang Hwee Min. Singapore's fertility rate drops to historic low of 0.87 as citizen population growth slows. Singapore: Channel News Asia; 2026 Feb 26.Available from: https://www.channelnewsasia.com/singapore/total-fertility-rate-tfr-2025-record-low-citizen-population-5954306
- Strategy Group (Prime Minister’s Office, Singapore). New Workgroup to Review Policies and Galvanise Societal Support for Marriage and Parenthood Reset. Singapore: Strategy Group(Prime Minister’s Office); 2026 Apr 29. Available from: https://www.strategygroup.gov.sg/new-workgroup-to-review-policies-and-galvanise-societal-support-for-marriage-and-parenthood-reset/
- European Society of Human Reproduction and Embryology. ART Fact Sheet. ESHRE; Nov Available from: https://www.eshre.eu/-/media/sitecore-files/Press-room/ESHRE_ARTFactSheet_v10_2025.pdf
- Pinborg A, Hougaard CO, Nyboe Andersen A, Molbo D, Schmidt L. Prospective longitudinal cohort study on cumulative 5-year delivery and adoption rates among 1338 couples initiating infertility treatment. Hum Reprod. 2009 Apr;24(4):991-9.
- Chambers GM, Sullivan EA, Ishihara O, Chapman MG, Adamson GD. The economic impact of assisted reproductive technology: a review of selected developed countries. Fertil Steril. 2009 Jun;91(6):2281-94.
- Tan T. Hospitals ramp up IVF capacity as more couples in Singapore seek medical help to have a baby. The Straits Times.2024 May 11. Available from: https://www.straitstimes.com/singapore/hospitals-ramp-up-ivf-capacity-as-more-couples-in-singapore-seek-medical-help-to-have-a-baby
- Ministry of Health, Waiting time for first assisted reproductive treatment appointment at public hospitals in past five years. Singapore: Ministry of Health; 2024 Apr 3. Available from: https://www.moh.gov.sg/newsroom/waiting-time-for-first-assisted-reproductive-treatment-appointment-at-public-hospitals-in-past-five-years/
- Lee Li Ying. MOH acts to curb growing influx of private patients into public sector with new IP rules: Ong Ye Kung. The Straits Time; 2025 Dec 14. Available from: https://www.straitstimes.com/singapore/moh-acts-to-prevent-growing-influx-of-private-patients-into-public-sector-with-new-ip-rules-ong-ye
- Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy: a committee opinion. Fertil Steril. 2024;122(3):421-34.
- Lin X, Wu D, Zhang C, Wang L, Lu Y, Zhou P, Zhou C, Jin L, Wang L, Zhu H, Pan J, Xu C, Chen S, Gao L, Li L, Zhang S, Wu Y, Sun Y, Mol BW, Huang H. Preimplantation genetic testing for aneuploidy versus no genetic testing in couples undergoing intracytoplasmic sperm injection for severe male infertility: multicentre, open label, randomised controlled trial. BMJ. 2025;391:e084050.
- The Guardian. Monash IVF reaches $56m settlement with 700 former patients after destroying potentially viable embryos. The Guardian. 2024 Aug 2Available from: https://www.theguardian.com/australia-news/article/2024/aug/22/monash-ivf-reaches-56m-settlement-with-700-former-patients-after-destroying-potentially-viable-embryos-ntwnfb
- Bioethics Advisory Committee, Singapore. Donation of Human Eggs for Research. Singapore: BAC; Nov 2008. Available from: https://www.bioethics-singapore.gov.sg/asian-bioethics-network/data-repository/donation-of-human-eggs-for-research/
- Ministry of Health, UPDATES ON PRICES AND PROCEDURES FOR ELECTIVE EGG-FREEZING IN SINGAPORE. Singapore: MOH; 2023 Jul 3. Available from: https://www.moh.gov.sg/newsroom/updates-on-prices-and-procedures-for-elective-egg-freezing-in-singapore/
- Chin AHB. Singapore needs to update regulation of frozen egg donation after permitting social egg freezing. J Assist Reprod Genet. 2022 Jul;39(7):1497-1500.
- Ethics Committee of the American Society for Reproductive Medicine. Financial compensation of oocyte donors: an Ethics Committee opinion. Fertil Steril. 2021;116(2):319-25.
- Scott K. More women are freezing their eggs for 'peace of mind'. But statistically, they're unlikely to use them. Australian Broadcasting Corporation. 2024 Oct 29. Available from: https://www.abc.net.au/news/2024-10-29/egg-freezing-on-the-rise-but-how-many-women-use-them/104501802
- Lee MB, Siavoshi M, Kwan L, Kroener L.Elective fertility preservation: a national database study on trends in oocyte cryopreservation and oocyte utilization over a 5- to 7-year follow-up period. Am J Obstet Gynecol. 2026 Feb;234(2):432-439.
- Inhorn MC. Informed opinion: the mating gap. Reprod Biomed Online. 2026 Apr 22;53(1):105732.
- Jadva V, Imrie S, Golombok S. Surrogate mothers 10 years on: a longitudinal study of psychological well-being and relationships with the parents and child. Hum Reprod. 2015;30(2):373-9.
- Chin AHB.Should Singapore legalize surrogacy to better protect all parties involved? J Forensic Leg Med. 2023 Jan;93:102464.
- Trimmings K, Beaumont P. International surrogacy arrangements: an urgent need for legal regulation at the international level. J Priv Int Law. 2011;7(3):627-47.
- Chin AHB.How IVG could challenge Singapore's laws on same-sex parenthood. UK: Progress Educational Trust (PET) BioNews; 2023 June 5. Available from: https://www.progress.org.uk/how-ivg-could-challenge-singapores-laws-on-same-sex-parenthood/
- Lim K. Singapore's single women 'not supported' even as egg-freezing rules are eased. South China Morning Post. 2023 May 20. Available from: https://www.scmp.com/week-asia/people/article/3221145/singapores-single-women-not-supported-even-egg-freezing-rules-are-eased
- Hayashi K, Saitou M. Generation of eggs from mouse embryonic stem cells and induced pluripotent stem cells. Nat Protoc. 2013;8(8):1513-24.
- Chin AHB, Alon I, Weerasekera TA, Bosenge-Nguma JD, Sun N.Ethical, Legal and Social Issues in Utilizing In Vitro Gametogenesis (IVG) and Stem Cell-Based Embryo Models (SCBEMs) for Human Reproduction in Singapore. Health Care Anal. 2025 Jun 12. doi: 10.1007/s10728-025-00521-6. Online ahead of print.
- Yamashiro C, Sasaki K, Yabuta Y, Kojima Y, Nakamura T, Okamoto I, Yokobayashi S, Murase Y, Ishikura Y, Shirane K, Sasaki H, Yamamoto T, Saitou M. Generation of human oogonia from induced pluripotent stem cells in vitro. Science. 2018;362(6412):356-60.
- Macpherson I, Roqué MV, Segarra I.Ethical Challenges of Germline Genetic Enhancement. Front Genet. 2019 Sep 3;10:767.
- Chin AHB, Villalba A, Alon I, Sun N, Yang J.Ethical challenges in extending mitochondrial replacement therapy (MRT) for overcoming poor egg quality in older women without mitochondrial diseases. J Assist Reprod Genet. 2025 Dec;42(12):4131-4141.
- Sharma H. Development of mitochondrial replacement therapy: a review. Heliyon. 2020;6(9):e04643.
- Joseph A, Molteni M. Births of eight healthy children show promise of mitochondrial replacement therapy.STAT News. 2025 Jul 16. Available from: https://www.statnews.com/2025/07/16/ivf-first-births-mitochondrial-replacement-therapy-united-kingdom/